Anaplastic Lymphoma Kinase Confers Resistance to BRAF Kinase Inhibitors in Melanoma

Melanoma frequently harbors oncogenic mutations in the BRAF gene, which drives melanoma growth. Therefore, BRAF kinase inhibitors (BRAFi) are developed and approved for treating BRAF-mutant melanoma. However, the efficacy of BRAFi is limited due to acquired resistance, and in over 40% of melanoma, t...

Descripción completa

Detalles Bibliográficos
Autores principales: Janostiak, Radoslav, Malvi, Parmanand, Wajapeyee, Narendra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6593146/
https://www.ncbi.nlm.nih.gov/pubmed/31229894
http://dx.doi.org/10.1016/j.isci.2019.06.001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6593146/
https://www.ncbi.nlm.nih.gov/pubmed/31229894
http://dx.doi.org/10.1016/j.isci.2019.06.001

Ejemplares similares